The downstream target of PRUNE1 is CD73, which catalyses adenosine monophosphate breakdown to adenosine during extracellular metabolism and has been found to be overexpressed in many types of cancer; however, CD73 is inhibited by low pH in the MM bone marrow microenvironment [21, 31]. Here, NT5E is linked to cancer.